NGM Biopharmaceuticals, Inc.
NGMNASDAQHealthcare
$1.54
$-0.02(-1.28%)
Market Cap$128532096
P/E Ratio—
52W High$4.69
52W Low$0.6002
NGM Biopharmaceuticals, Inc. (NGM) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NGM · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($142.38M) | ($162.67M) | ($120.33M) | ($102.49M) | ($42.80M) |
| Depreciation & Amort. | $2.22M | $4.04M | $6.09M | $6.55M | $7.61M |
| Stock-Based Comp. | $28.72M | $32.38M | $26.24M | $15.65M | $12.98M |
| Change in Working Capital | ($18.38M) | ($20.71M) | $4.21M | ($3.70M) | ($17.94M) |
| Net Cash from Operations | ($132.20M) | ($144.44M) | ($73.23M) | ($83.50M) | ($41.17M) |
| Investing Activities | |||||
| Capital Expenditure | ($1.25M) | ($1.86M) | ($1.68M) | ($1.88M) | ($3.49M) |
| Purchases of Investments | ($105.43M) | ($272.86M) | ($293.47M) | ($177.66M) | ($134.31M) |
| Sales of Investments | $220.97M | $289.04M | $223.50M | $128.54M | $186.52M |
| Net Cash from Investing | $114.29M | $14.32M | ($71.65M) | ($51.00M) | $48.72M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $1.77M | $54.23M | $149.66M | $35.54M | $180.75M |
| Free Cash Flow | |||||
| Free Cash Flow | ($133.45M) | ($146.30M) | ($74.91M) | ($85.38M) | ($44.66M) |
| FCF Margin %(computed) | — | -264.39% | -96.19% | -97.72% | -43.13% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more NGM Biopharmaceuticals, Inc. data
About NGM Biopharmaceuticals, Inc. (NGM) Cash Flow Statement
NGM Biopharmaceuticals, Inc. generated operating cash flow of ($0.13B) and free cash flow of ($0.13B) for 2023 — a FCF margin of -3021.37%. Capital expenditure was ($0.00B).
Frequently asked questions
NGM · 4 questionsNGM Biopharmaceuticals, Inc. generated free cash flow of ($0.13B) for 2023, up 8.8% year-over-year.
NGM free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10